Term
|
Definition
| IP3 and DAG, increased intracellular Ca |
|
|
Term
|
Definition
| inhibition of adenylyl cyclase, decreased cAMP |
|
|
Term
|
Definition
| stimulation of adenylyl cyclase, increased cAMP |
|
|
Term
|
Definition
| stimulation of adenylyl cyclase, increased cAMP |
|
|
Term
|
Definition
| stimulation of adenylyl cyclase, increased cAMP |
|
|
Term
|
Definition
| stimulation of adenylyl cyclase, increased cAMP |
|
|
Term
| D2-D4 signal transduction |
|
Definition
| inhibition of adenylyl cyclase, decreased cAMP |
|
|
Term
|
Definition
| non-selective (a1,a2,b1,b2,b3), direct receptor agonist |
|
|
Term
|
Definition
| Nonselective, structural analogue of NE, indirectly causes the release of NE by increasing intracellular concentration of itself (mass action) in the cytoplasm and vesicle. NE leaves via the same pump (NOT EXOCYTOTIC) |
|
|
Term
|
Definition
| Nonselective, structural analogue of NE, indirectly causes the release of NE by increasing intracellular concentration of itself (mass action)in the cytoplasm and vesicle. NE leaves via the same pump (NOT EXOCYTOTIC) |
|
|
Term
|
Definition
| nonselective, inhibits reuptake |
|
|
Term
| Tricyclic antidepressants |
|
Definition
| Nonselective, inhibits reuptake indirect |
|
|
Term
|
Definition
| a1,a2,b1 (selective adrenergic receptor agonist) |
|
|
Term
|
Definition
| a1>a2, (selective adrenergic receptor agonist) |
|
|
Term
|
Definition
| b1 and b2 (selective adrenergic receptor agonist) |
|
|
Term
|
Definition
| b1 (selective adrenergic receptor agonist) |
|
|
Term
|
Definition
| b2 (selective adrenergic receptor agonist) |
|
|
Term
| Addition of bulky groups to the amine of adrenergic agonists--> |
|
Definition
| beta selectivity (Epinephrine has > beta selectivity than NE) |
|
|
Term
| beta carbon hydroxy group on adrenergic agonists--> |
|
Definition
| more direct activity: Epi, NE, isoproterenol (less indirect activity: tyramine, amphetamine) |
|
|
Term
| methyl addition to the alpha carbon of adrenergic agonists--> |
|
Definition
| resistance to MAO degradation; increases bioavailability (Epi cannot be taken orally bc it does not have an a-carbon methyl group and is rapidly degraded) |
|
|
Term
| Removal of catechol group of adrenergic agonists |
|
Definition
| resistant to catechol-o-methyl transferase |
|
|
Term
|
Definition
|
|
Term
| renal vasculature contains what receptor |
|
Definition
| Dopamine-->dilation of the vasculature |
|
|
Term
|
Definition
| dilation of pupil, vasoconstriction (dysautonomia/local hemostasis), incontinence, decongestion, |
|
|
Term
|
Definition
| heart failure, cardiogenic shock (ischemia, CAD) |
|
|
Term
|
Definition
| suppression of premature labor, asthma |
|
|
Term
|
Definition
| cardiac failure, during hemorrhage to increase renal perfusion |
|
|
Term
|
Definition
| Anaphalaxis: vasoconstriction, decongestion (a1), cardiac stimulation (b1), bronchodilation (b2) |
|
|
Term
|
Definition
| ADHD, weight loss, narcolepsy |
|
|
Term
|
Definition
| HTN (hemorrhagic stroke, MI, PE) |
|
|
Term
|
Definition
| excessive cardiac stimulation (MI, arrhythmias) |
|
|
Term
|
Definition
|
|
